Clonal Hematopoiesis in Hematologic Malignancies, Bone Marrow Failure Syndromes, and Stem Cell Clones
Recent studies have better elucidated the link between clonal hematopoiesis and hematologic malignancies.
Recent studies have better elucidated the link between clonal hematopoiesis and hematologic malignancies.
The FDA has approved Reblozyl® (luspatercept–aamt; Bristol-Myers Squibb and Acceleron) for the treatment of anemia in adults with lower-risk myelodysplastic syndromes.
Data from an ongoing trial of luspatercept, an erythroid maturation agent, in patients with myelofibrosis and anemia shows promise of clinically significant activity with low level of grade 3/4 adverse effects.
What are the recommendations for managing anemia in patients receiving olaparib?
Less than 10% of patients developing severe chemotherapy-induced anemia did not have any of the identified potential patient-related risk factors.
Researchers reviewed cancer incidence in patients with Diamond-Blackfan anemia.
Managing anemia in patients with myelodysplastic syndrome (MDS) is complex. When are erythroid growth factors used as primary treatment?
In following patients with anemia, what do the lab values for iron, ferritin, transferrin, and TIBC (total iron binding capacity) tell me?
Adding the ESA epoetin alfa to the chemotherapy regimen for high-risk breast cancer improved hemoglobin levels for patients, but it also resulted in increased thrombosis.
Chemotherapy-induced nerve injury in the bone marrow is what impairs the regeneration of hematopoietic stem cells, leading to anemia.